Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Featured Story

Who decides when vaccine studies are done? Internal documents show Fauci plays a key role

By Isaac Arnsdorf, Caroline Chen and Ryan Gabrielson, ProPublica

Dr. Anthony Fauci will see data from government-funded vaccine trials before the FDA does. One caveat: Pfizer’s study, which is ahead of the others, isn’t included in his purview.

3 ways a Biden White House could impact healthcare

By Robert King

How would a Joe Biden White House impact the healthcare industry? Here's what several experts had to say about what to watch as the election nears.

Lab survey illustrates testing delays spreading to non-COVID diagnostic areas

By Conor Hale

Despite widespread increases in the production of COVID-19 test kits this year, about three-out-of-four surveyed U.S. laboratories still report that they do not have enough supplies to meet the pandemic’s demand.

Global healthcare funding hit a record in Q3. Here's how much digital health companies raised

By Heather Landi

Global healthcare funding soared in the third quarter, hitting a new record of $21.8 billion across 1,539 deals. Here are the sectors drawing the most interest from investors.

Biopharma roundup: J&J's trial pause still 'unexplained'

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

Anthony Fauci will oversee data on many U.S. shot trials, but not Pfizer's, ProPublica reports. J&J's lack of transparency on its clinical hold drew fire from health experts. The National Governor's Association is demanding to know exactly how a shot rollout will work. And a price tag for Sinovac's shot has emerged.

Evotec nabs Gates Foundation cash for low-income country COVID-19 antibody work

By Ben Adams

German biotech-CRO hybrid Evotec has been handed a lump sum to help develop the next generation of antibodies to treat patients sick with COVID-19.

LabCorp launches COVID-19 antibody test for measuring vaccine effectiveness

By Conor Hale

LabCorp has launched a new COVID-19 antibody test designed to gauge the strength of a person’s immune response to the virus, for use in clinical trials of potential vaccines and therapies.

KFF: ACA premiums to rise by 1% in 2021 amid COVID-19 uncertainty

By Robert King

Premiums on the Affordable Care Act's exchanges are expected to rise slightly next year, but insurers are still struggling to figure out how COVID-19 will impact healthcare costs, report finds.

Aligos, Tarsus bank $238M as biotech IPO party continues

By Amirah Al Idrus

Let’s add two more to the list—a pair of clinical-stage biotechs collectively raised more than $200 million in their Nasdaq debuts. Hepatitis B and COVID-19-focused Aligos Therapeutics raised $150 million, while eye disease player Tarsus Pharmaceuticals reeled in $88 million.

Antimicrobial posters: In-office content provider gives ad boards a COVID-19-safe refresh

By Beth Snyder Bulik

While many healthcare professionals enjoy the camaraderie of office lunchrooms, they probably don’t want extra contagions with their sandwiches—especially during the COVID-19 pandemic. So Physician’s Weekly, the veteran editorial and pharma advertising newsletter-like wallboard provider, decided to take an extra step to make sure its posters were safe.

COVID-19 Tracker